CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

DaclatasvirWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (8)

Name (Synonyms) Correlation
drug1835 Placebo Sofusbuvir + Daclatasvir Wiki 0.71
drug234 Atazanavir Wiki 0.71
drug1831 Placebo Daclatasvir Wiki 0.71
drug2283 Sofusbuvir + Daclastavir Wiki 0.71
drug770 Digital cardiac Counseling Wiki 0.71
drug3004 sofosbuvir Wiki 0.71
drug1829 Placebo Atazanavir Wiki 0.71
drug2092 Ribavirin Wiki 0.50

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002318 Cardiovascular Diseases NIH 0.15
D007239 Infection NIH 0.04

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.15

There are 2 clinical trials

Clinical Trials

1 Sofosbuvir With and Without Ribavirin in Treatment of COVID 19 Patients

Sofosbuvir with and without ribavirin in treatment of COVID 19 Egyptian patients

NCT04460443 COVID Drug: sofosbuvir Drug: Ribavirin Drug: Daclatasvir

Primary Outcomes

Description: The total number of patients with response to treatment

Measure: Number of patients with response to treatment

Time: 1 month

2 Antiviral for Adult Patients Hospitalized for SARS-CoV-2 Infection: a Randomized, Phase 2/3, Multicenter, Double Blinded, Placebo Controlled, Adaptive, Multi-arm, Multi-stage Clinical Trial - Coalition Brazil COVID-19 IX

A key strategy in the treatment of COVID-19 would be to find an effective antiviral agent that would decrease the peak viral load and, consequently, the associated degree of immunopathological damage that follows this phase. The clinically approved substances considered for this study are used for treatment of other virus diseases, like HIV (atazanavir) and HCV (sofosbuvir and daclatasvir). Severe progression of COVID-19 among patients under treatment for these aforementioned viruses is empirical less common. Besides, the clinical rationale, there are pre-clinical evidence pointing out that patients with COVID-19 could benefit from treatments with atazanavir, sofosbuvir and daclatasvir.

NCT04468087 COVID-19 Drug: Atazanavir Drug: Daclatasvir Drug: Sofusbuvir + Daclastavir Drug: Placebo Atazanavir Drug: Placebo Daclatasvir Drug: Placebo Sofusbuvir + Daclatasvir
MeSH:Infection

Primary Outcomes

Description: Change in area under the SARS-COV 2 viral load curve evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization (isolated antiviral).

Measure: Phase II first step: Change in area under the curve of SARS-COV 2 viral load

Time: days 3, 6 and 9 after randomization

Description: Change in area under the SARS-COV 2 viral load curve evaluated by nasopharyngeal swab samples assessed at baseline and days 3, 6 and 9 after randomization (combined antiviral).

Measure: Phase II second step: Change in area under the curve of SARS-COV 2 viral load

Time: days 3, 6 and 9 after randomization

Description: Number of days without oxygen, non-invasive ventilation/high flow nasal cannula or need for mechanical ventilation in 15 days.

Measure: Phase III: Number of free days from respiratory support

Time: 15 days

No related HPO nodes (Using clinical trials)